Pharmafile Logo
Pharmafocus logo
Advanced Search

Bristol-Myers Squibb

Showing 15 posts of 146 posts found.

shutterstock_273326141

BMS and Array BioPharma partner up to tackle colorectal cancer

May 30, 2017
Manufacturing and Production, Research and Development, Sales and Marketing Array Biopharma, BMS, Bristol-Myers Squibb

Bristol-Myers Squibb and Array BioPharma have announced they are to join forces as part of a new clinical research partnership …

News
thomas_headshot

BMS finds replacement for retiring CSO

March 9, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb

Bristol-Myers Squibb has announced the appointment of Dr. Thomas J. Lynch, Jr., to the position of Executive Vice President and …

Appointment
2000px-bristol-myers_squibb_logo

BMS temporarily expands Board with three new additions

February 23, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb

Bristol-Myers Squibb has bolstered its Board of Directors with the appointment of three Directors, a move which temporarily expands its …

Appointment
keytruda3-web

MSD aims to get the jump on BMS treating bladder cancer

February 6, 2017
Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, MSD, keytruda, opdivo

Bristol-Myers Squibb’s Opdivo was only just approved for second-line treatment of bladder cancer, but MSD has attempted to have its …

News

FDA clears Opdivo to treat most common form of bladder cancer

February 6, 2017
Sales and Marketing BMS, Bristol-Myers Squibb, MSD, bladder cancer, immunotherapy, keytruda, opdivo

Bristol-Myers Squibb’s Opdivo has acquired another indication – being given the go-ahead for treatment of patients with metastatic urothelial carcinoma. …

News
joe_biden_and_obama

New formulary ‘bank’ to aid research into combination therapies

January 11, 2017
Medical Communications, Research and Development 21st Century Cures Act, Bristol-Myers Squibb, Eli Lilly, Joe Biden, Obama, bristol myers-squibb, combination therapy

As part of the wider ‘cancer moonshot’ initiative, confirmed by the signing of the 21st Century Cures Act by Obama, …

News
giovanni_caforio

Giovanni Caforio to be made chairman of the board at BMS

January 3, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, Giovanni Caforio, bristol myers-squibb

Bristol-Myers Squibb has announced that Giovanni Caforio has been appointed chairman of the board. Caforio will take up the position …

Appointment
bristol

Opdivo first PD-1 inhibitor given European approval for haematological cancer

November 25, 2016
Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, EMA, PD1-Inhibitor, bristol myers-squibb

Bristol-Myers Squibb announced that it has received the first and only European approval for a PD1 inhibitor in the treatment …

News
humacao_exterior

NICE thumbs up for BMS leukaemia treatment

November 18, 2016
Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, NICE, Sprycel, chronic myeloid leukaemia

Bristol-Myers Squibb has announced that NICE have given a Final Appraisal Determination recommending Sprycel (dasatinib) for the treatment of chronic …

News

Blood cancer sufferers to receive early access to BMS’ Opdivo

November 3, 2016
Medical Communications Bristol-Myers Squibb, lyphoma, opdivo

Bristol-Myers Squibb has announced that their immunotherapy drug, Opdivo (nivolumab), will be made available to patients in the UK through …

News
humacao_exterior

BMS unveils reorganisation plans & boosted profits

October 28, 2016
Business Services, Medical Communications Bristol-Myers Squibb, Yervoy, opdivo

BMS has announced its intention to restructure its operations alongside $3 billion share buyback and quarterly results which exceeded expectations.The …

News
opdivo_1

FDA accepts another Opdivo indication for priority review

October 24, 2016
Sales and Marketing BMS, Bristol-Myers Squibb, FDA, opdivo

The FDA has accepted a supplemental Biologics License Application (sBLA) for Bristol-Myers Squibb’s Opdivo for treatment of locally advanced unresectable …

News
msd_merck_night_building

MSD’s Keytruda twice as successful against standard therapy for lung cancer

October 10, 2016
Sales and Marketing Bristol-Myers Squibb, MSD, Merck, keytruda

MSD, known as Merck in North America, released data that displayed the success of their drug, Keytruda, in a 123-patient …

News
bms

European Commission approves new RA treatment from BMS

September 6, 2016
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, EMA, EU, Orencia, RA, abatacept, approval, rheumatoid arthritis

Bristol-Myers Squibb has received approval from the European Commission for rheumatoid arthritis (RA) treatment Orencia (abatacept), making it the first …

News
pharmafocus_sept_2016_cover

The September issue of Pharmafocus is now live!

August 31, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myer's Squibb, Bristol-Myers Squibb, CDF, Cancer Drugs Fund, Cloud Computing, Pharmafocus, Pharmafocus new issue, brexit, clinical trial transparaency, opdivo

The latest edition of Pharmafocus is available online now. In this issue, we explore the future of the clinical trial …

News

Latest content

Regeneron shares data for multiple myeloma treatment

December 8, 2023

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023

ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development

December 7, 2023

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023